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RESULTS: 2,657 patients were included in this analysis.
Initial and overall mean daily doses were 12.2 and 13 mg
for olanzapine, 5.2 and 5.4 mg for risperidone, and 13.9
and 13.6 mg for haloperidol. Median daily doses were 10
mg for olanzapine, 6 mg for risperidone, and 10 mg for
haloperidol. Significantly (p 	 0.001) lower proportion of
olanzapine-treated patients (36.9%) experienced EPS than
risperidone (49.6%) and haloperidol (76.0%) patients.
Significantly (p 	 0.001) lower proportion of olanzapine-
treated patients (47.8%) experienced any adverse event
than risperidone (57.2%) and haloperidol (79.8%) pa-
tients. Significantly (p  0.05) greater proportion of olan-
zapine-treated patients (37.3%) were responders than ris-
peridone patients (31.5%). Patients who had an initial
CGI 	5 had significantly (p  0.001) higher overall mean
daily doses than patients with an initial CGI 5. Signifi-
cantly (p  0.001) lower proportion of olanzapine-treated
patients (10.2%) were receiving concomitant anticholin-
ergic medication at the end of the study than risperidone
(19.9%) and haloperidol (44%) patients. Significantly (p 
0.001) lower proportion of olanzapine-treated patients
(18.4%) were receiving other antipsychotics at the end of
the study than risperidone patients (25.6%).
CONCLUSION: Mean daily doses from a naturalistic set-
ting were consistent with recommendations based on clini-
cal trials. Olanzapine-treated patients were less likely to
experience EPS, any adverse event, or use of anticholin-
ergic medications than risperidone and haloperidol pa-
tients were. Olanzapine-treated patients were less likely to
receive other antipsychotic medications and more likely to
experience a response than risperidone patients.
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OBJECTIVES: A pharmacoeconomic analysis of schizo-
phrenia treatment with olanzapine, risperidone and halo-
peridol in Germany.
METHODS: A decision model, which included clinical
parameters, that was previously developed by an interna-
tional expert panel was used. Medical resource utiliza-
tion and costs in Germany were determined by a German
expert panel and integrated into the model. Subse-
quently, a cost analysis, a cost-effectiveness analysis and
a cost-utility analysis were performed.
RESULTS: The total costs per patient for 5 years were
highest for risperidone (DM 123 004). Total costs for ha-
loperidol were DM 121 868 and total costs for olanzap-
ine amounted to DM 119 572. Cost-effectiveness of ris-
peridone and olanzapine compared to haloperidol was
better by the factor 2.3 and 2.5, respectively. The costs
per quality-adjusted-life-year were lowest for olanzapine
followed by risperidone and haloperidol.
CONCLUSION: If total costs are considered, the high
medication costs of new antipsychotics are compensated
by savings due to better efficacy in treatment of negative
symptoms and less relapses.
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OBJECTIVES: To compare costs and characteristics of
migraine patients receiving triptan therapy versus those
not receiving triptan therapy.
METHODS: All patients possessing a migraine diagnosis
(ICD-9-CM  346) in the PharMetrics Integrated Out-
comes Database over the age of 18 between January 1,
1997 and March 31, 1998 were eligible for inclusion. Sub-
jects were required to be in the database for at least 3
months prior to and 3 months following the index date.
Any subject receiving migraine treatment prior to their
first diagnosis was excluded from the study. Subjects were
categorized as being in either the triptan or non-triptan
treatment groups based on the presence of a triptan pre-
scription during the 90 days following their index date.
Subject demographics, comorbidities and utilization of
other migraine treatments were assessed, and compared
across treatment groups. Charges were captured over a 90-
day period following the index date.
RESULTS: A total of 8,018 patients met the inclusion cri-
teria. Approximately 85% were female and the mean age
was 41.62 (Std. Dev  12.64). Over 90% did not receive a
triptan prescription within 90 days of the index date. Hy-
pertension was less commonly observed in triptan users;
all other comorbidities occurred equally in both groups.
Triptan users were more likely to consume other anti-
migraine drugs than non-triptan users. Costs were very
similar in triptan users (mean  $1751 Std. Dev.  4142)
and non-triptan users (mean  $1613 Std Dev 5193).
CONCLUSIONS: Triptans did not appear to be com-
monly prescribed following an initial migraine diagnosis.
Despite increased anti-migraine drug usage in triptan us-
ers, costs between triptan and non-triptan users were very
similar.
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OBJECTIVE: To assess the feasibility of using interna-
tional disease-specific, cross-sectional databases for phar-
macoeconomic research.
METHODS: We evaluated several large international
cross-sectional, disease-specific databases for their appro-
priateness in early and late phase research. A migraine da-
tabase is presented as an example. The migraine database
contained 699 physicians and 8,537 subjects in 6 coun-
tries.
RESULTS: Data elements could be used in modeling, cost
of care, patient segmentation, and cost-effectiveness stud-
ies. For example, average resource use for France, Ger-
many and the US for PCP visits (over the previous 12
months) was 3.3, 4.0, and 4.3 days, respectively. Inpatient
hospitalization days for the same countries were 0.1, 0.1
and 1.9, respectively. For modeling purposes, transition
probabilities could be based on the length of the migraine
attack (in France): 25 hours without treatment and 7
hours with treatment. Lost work time, important to mi-
graineurs, was examined by severity group. During the
previous 6 months lost time from work for moderate mi-
graines for France, Germany and the US was 11.4, 4.5,
and 4.8, respectively. For severe patients, lost work time
was 6.6, 6.2, and 7.8 days, respectively.
CONCLUSIONS: International databases offer some in-
formation useful for PE research. Their strength relies on
the large number of patients and the validity of the data is
higher than using experts to estimate resource utilization.
In addition, the international aspect of the database facili-
tates cross-country comparisons and the adaptation of
models to local settings.
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This study reports the results of a long-term cost effective-
ness analysis of riluzole in the treatment of amyotrophic
lateral sclerosis (ALS) in the United Kingdom. Long term
analysis was carried out using Markov modelling extrapo-
lating the transition probabilities derived from clinical trial
data. The implications of life extension offered by riluzole
were assessed in terms of the time spent in each health
state which ALS patients experience. This data was taken
from a cohort of 954 patients drawn from a large random-
ized, double blind, placebo controlled, multi-center trial
between 1992 and 1994.
RESULTS: Findings suggest that riluzole is effective in
prolonging life and that a larger proportion of patients
treated with riluzole will stay longer in states where func-
tional status is least impaired. The additional life expect-
ancy of the intervention over the three-year period sug-
gests that treatment of three patients for three years would
result in obtaining one additional life-year. Riluzole offsets
approximately half the additional costs of treatment
through extending the time that patients spend in the
milder phases. Therefore, cost per unadjusted additional
life-year gained was estimated at £8,587 over the expected
lifetime of ALS patients. The findings also show that incre-
mental cost figures are not sensitive to the cost of health
states.
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OBJECTIVES: As part of a multi-national, observational
investigation of the quality of life and economic correlates
of recognized major depression in primary care (the LIDO
study), to develop a research method for the collection of
a) individual health care service utilisation and associated
costs data, and b) site-level socio-demographic and service
profiles.
METHODS: Alternative approaches to the collection and
aggregation of data relating to the utilisation, cost, struc-
ture and provision of local health services were reviewed,
together with relevant existing instruments. An iterative
process of cross-cultural validation was pursued in order
to ensure standardized definitions and semantic equiva-
lence of services across sites.
RESULTS: Three sets of instrumentation were developed:
1) a “local socio-demographic and service profile” sched-
ule giving data on key socio-demographic indicators and
primary/secondary care service characteristics at the local,
regional and national level of each participating site; 2) an
interviewer-led resource utilisation questionnaire contain-
ing internationally comparable items of potential service
receipt (subsequently translated into local site languages
and incorporated into the assessment of each recruited
study subject); and 3) a set of unit cost templates for all
itemized services, based on a common protocol and stan-
dardized methodology. Both “purchasing power parities”
and a “market basket” approach were used (and com-
pared) as the basis for converting national service costs
into a single currency for the purposes of pooled analyses.
A conceptual model depicting the inter-relationship be-
tween costs, depressive symptoms and quality of life was
constructed in order to generate and structure study hy-
potheses and modes of analysis.
CONCLUSION: Cross-cultural comparison of health ser-
vice utilisation and costs is complicated by the heterogene-
ity of service systems and the need to reflect the contexts
within which people live and receive their care. In order to
be locally meaningful yet internationally comparable, a
carefully constructed approach towards data collection is
required.
